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Abstract
Objective: To determine whether predicted fork stalling and template switching
(FoSTeS) during mitosis deletes exon 4 in peripheral myelin protein 22 KD
(PMP22) and causes gain-of-function mutation associated with peripheral neu-
ropathy in a family with Charcot–Marie–Tooth disease type 1E. Methods: Two
siblings previously reported to have genomic rearrangements predicted to
involve exon 4 of PMP22 were evaluated clinically and by electrophysiology.
Skin biopsies from the proband were studied by RT-PCR to determine the
effects of the exon 4 rearrangements on exon 4 mRNA expression in myelinat-
ing Schwann cells. Transient transfection studies with wild-type and mutant
PMP22 were performed in Cos7 and RT4 cells to determine the fate of the
resultant mutant protein. Results: Both affected siblings had a sensorimotor
dysmyelinating neuropathy with severely slow nerve conduction velocities
(<10 m/sec). RT-PCR studies of Schwann cell RNA from one of the siblings
demonstrated a complete in-frame deletion of PMP22 exon 4 (PMP22D4).
Transfection studies demonstrated that PMP22D4 protein is retained within the
endoplasmic reticulum and not transported to the plasma membrane. Conclu-
sions: Our results confirm that that FoSTeS-mediated genomic rearrangement
produced a deletion of exon 4 of PMP22, resulting in expression of both
PMP22 mRNA and protein lacking this sequence. In addition, we provide
experimental evidence for endoplasmic reticulum retention of the mutant pro-
tein suggesting a gain-of-function mutational mechanism consistent with the
observed CMT1E in this family. PMP22D4 is another example of a mutated
myelin protein that is misfolded and contributes to the pathogenesis of the
neuropathy.
Introduction
Charcot–Marie–Tooth (CMT) disease is the most com-
mon inherited peripheral neuropathy affecting approxi-
mately 1:2500 individuals.1 Roughly half of these patients
have CMT1A,2 a demyelinating neuropathy caused by a
1.4-Mb duplication in chromosome 17p12 that contains
the peripheral myelin protein 22 gene, PMP22, an integral
membrane protein expressed in PNS compact myelin.3,4
CMT1A is hypothesized to occur as a result of nonallelic
homologous recombination (NAHR)5–7 in a region of
17p12 surrounding and including the PMP22 gene, caus-
ing increased expression of the normal gene product.
Point mutations in PMP22 gene can cause a relatively
severe demyelinating or dysmyelinating peripheral neu-
ropathy, in which myelin never forms normally during
development. Mutations within the PMP22 gene are clas-
sified as CMT1E.2 Most CMT1E mutations are missense
mutations probably resulting in a gain-of-new protein
function.8 In contrast, some PMP22 point mutations
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produce a loss-of-protein function by a shift in the protein
reading frame, leading to premature termination of transla-
tion.9–12 A similar loss of function can also be caused by
the reciprocal deletion of PMP22 within 17p12 that caused
the CMT1A duplication. Loss of PMP22 function leads to
an electrophysiologically distinct inherited neuropathy
known as hereditary neuropathy with pressure palsies.13
Recently, it was proposed that abnormalities of fork
stalling and template switching (FoSTeS) or microhomol-
ogy-mediated break-induced replication (MMBIR) caused
a complex rearrangement within an individual PMP22
allele that resulted in CMT1 in a family in which two sib-
lings, but neither parent, developed CMT1.14 The rear-
rangements were identified in DNA from white blood
cells and were hypothesized to result from three separate
FoSTeS/MMBIR-mediated template switching events that
were predicted to specifically disrupt the sequence of
PMP22 exon 4 in the patients. The mother was found to
be mosaic for the same rearrangement with lower levels
in the mutated allele in her WBC. Both siblings had
markedly reduced nerve conduction velocities, whereas
the conduction velocities of the mother were normal.
We had the opportunity to examine both affected siblings
and further test this hypothesis by evaluating PMP22 expres-
sion from myelinated nerves obtained from skin biopsies.
RT-PCR analysis from the skin biopsies revealed the absence
of exon 4 sequences in PMP22 mRNA, consistent with the
analysis of genomic DNA as described by Zhang and
coworkers. Transfection studies demonstrated that the
mutant protein is retained in the endoplasmic reticulum,
which is the most parsimonious explanation for its patho-
genesis via a gain-of-function mutational mechanism.
Methods
Clinical evaluation
The two siblings were evaluated clinically at the Univer-
sity of Iowa CMT clinic at ages 9 and 13 years. Neurolog-
ical examination and neurophysiological and skin biopsy
studies were performed on the patients during their clinic
visit. A skin biopsy was obtained following informed con-
sent as part of an orthopedic procedure at Washington
University, St. Louis. Informed consent according to the
Declaration of Helsinki and the Institutional Review
Boards at the participating centers approving the study
was obtained from both siblings and their parents.
Skin biopsy and RT-PCR
The skin sample was evaluated as described previously.15
The sample was treated in freshly prepared RNALater
(Qiagen, CA, Cat. No.: 1017980). RNA was isolated with
RNeasy Micro Kit (Qiagen, CA, Cat. No.: 74004) followed
by the RT reaction in SuperScript First-Strand Synthesis
System for RT-PCR (Invitrogen, CA, Cat. No.: 12371-
019) and then the PCR in Platinum Pfx DNA Polymerase
(Invitrogen, CA, Cat. No.: 11708-013). The upstream and
downstream primers were 50-GGGCAGAAACTCCGCT-
GAGCAGAA-30 and 50-GTACGCTCAGCGCCTCAGACA-
GAC-30, respectively. PCR conditions were 95°C 2 min/
95°C 15°sec, 60°C 30°sec, 68°C 1 min for 35 cycles/68°C
10 min. Sanger sequencing was performed to analyze the
products after cloning with Zero Blunt TOPO PCR Clon-
ing Kit with One Shot TOP10 Electrocamp Chemically
Competent Escherichia coli (Invitrogen, CA, Cat. No.:
K2860-20).
Preparation of wild-type and mutant PMP22
constructions
The cDNAs encoding both wild-type and mutant human
PMP22 mRNA sequences were synthesized from the
patient’s skin biopsy RNA by RT-PCR and cloned into an
expression vector with an HA tag at its 30 end (Cat. No.:
A921149-1, Lucigen Corp. Middleton, WI). The HA tag
was obtained from the pME-HA vector (Cat. No.:
A921149-1). Both of these constructs were used in the
transfection studies described below.
Cell culture, transfection, and
immunocytochemistry
Cos 7 cells (American Type Culture Collection) and RT4
rat Schwann cells (Gift from Dr. John Svaren) were sepa-
rately grown on four-well chamber slides in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal
bovine serum and 1% penicillin–streptomycin and trans-
fected with 2-lg plasmid DNA using LipofectamineTM
3000 (Invitrogen). Cells were transfected with the follow-
ing plasmids: (1) WT-PMP22, (2) PMP22-exon 4 deletion
– each plasmid with the hemagglutinin epitope tag fused
to the N-terminus. Forty-eight hours after transfection,
immunocytochemistry was carried out as described previ-
ously16). In brief, cells were rinsed twice in PBS for 5 min
and then fixed in 4% paraformaldehyde for 5 min. After
being washed three times in PBS, cells were incubated
with primary antibodies at 4°C overnight: Antihemagglu-
tinin (anti-HA), 1:1000 (Cell Signaling Technology
Cat#2367 [mouse]; #3724 [rabbit]); anticalnexin (marker
for endoplasmic reticulum), 1:300 (Abcam, Cat#
ab22595); antigiantin (marker for Golgi apparatus), 1:300
(Abcam, Cat# ab37266). Following three 10-min washes
in PBS and 1 h incubation with secondary antibodies
(Cy3-conjugated donkey anti-rabbit IgG, Jackson
Immuno Research, Cat#711-165-152 or anti-mouse,
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Cat#711-165-1521; fluorescein [FITC]-conjugated Affini-
Pure Donkey anti-mouse IgG, cat#712-095-151; or anti-
rabbit IgG cat#711-095-152), the coverslips were mounted
applying Anti-Fade 4-6-diamino-2-phenylindole (DAPI)
mounting media that labeled nuclei (Invitrogen Cat#
P36931).
We determined the transfection efficiency by taking 10
images under 40 9 objective lens per group; WT-PMP22
and PMP22-exon 4 deletion. HA-tag-labeled cells were
counted as a positively transfected cell. We then divided
this number by total nuclei number stained with DAPI.
Transfected RT4 cells were imaged (9 63 magnification,
repeated 3 times) magnification with a Zeiss 710 confocal
microscope in order to demonstrate cell surface expres-
sion, endoplasmic reticulum or Golgi retention of
PMP22-exon 4 deletion mutation or PMP22wt. The num-
ber of colocalized cells that showed overlap of HA-
PMP22 and ER or Golgi was divided by the total number
of transfected cells to obtain percentage of colocalization.
Results
Clinical summary
We evaluated two sisters who had been previously
demonstrated to have complex rearrangement of PMP22
exon 4 that they had inherited from their asymptomatic
mother who was mosaic for this unusual mutation.17
Both sisters had evidence of a significant sensorimotor
dysmyelinating peripheral neuropathy that began in
Figure 1. Ultrasound of gastrocnemius and femoral nerves. Transverse images of the quadriceps femorus muscle (top panel) obtained from
younger sister show increased echointensity bilaterally and relatively reduced thickness on the left. Dotted lines demonstrate the thickness of the
muscle. Longitudinal images of the femoral nerve at the inguinal ligament (bottom panel) shows bilateral nerve enlargement. Femoral nerve is
shown between arrows.
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infancy. Neither sister walked independently until 16–
17 months of age. The older sister was diagnosed based
on diffuse weakness and absent deep tendon reflexes prior
to the age of 2. She was initially thought to have chronic
inflammatory demyelinating polyradiculoneuropathy
(CIDP), received treatment with periodic intravenous
gamma globulin (IVIG) between ages 2 and 3½, but she
did not improve. The IVIG was discontinued when the
younger sister was also found to have neuropathy and it
was realized that the neuropathy was probably genetically
based. The older sister presented to us with symmetrical
bilateral foot drop. She had been prescribed ankle foot
orthotics (AFOs) that she initially rarely wore. At age 13,
she did not consider balance to be a major problem and
was falling rarely. She denied difficulties with fine hand
movements such as manipulating buttons, zippers, writ-
ing, or manipulating small objects. Two years later she
was falling more frequently and was using AFOs regularly,
at least for longer distances. The younger sister was
thought by her parents to be more severely affected in
part because of asymmetrical proximal weakness of the
left leg, which began to develop at between the ages of 7
and 8 years. She was diagnosed with mild hip dysplasia
on the right, asymptomatic side for which she underwent
surgery. However, the asymmetrical weakness on the left
progressed until the left hip extensor strength was only 2/
5 MRC scale. Ultrasound at age 10 showed reduced thick-
ness of the left leg muscles including the quadriceps
(Fig. 1A). However, ultrasound studies also showed
enlargement of both right and left femoral nerves
(Fig. 1B) as was the case with other nerves evaluated
(data not shown). Additionally, ultrasound of both sisters,
ages 2 and 6 years, showed diffuse nerve enlargement,
with median and ulnar nerves three to five times larger
than normal (data not shown). The possibility of a super-
imposed inflammatory component was considered at age
10 and she responded to twice weekly corticosteroid treat-
ment with return of measurable strength in left quadri-
ceps and iliopsoas (4/5 MRC). At age 11 years, the
younger sister does use the elevator at school to go
upstairs. The clinical examination of both siblings is pro-
vided in Table 1. Motor nerve conduction velocities












































Motor weakness based on MRC scale (0–5): + = weakness present, – = no weakness detected. LL distal weakness assessed by anterior tibialis and
gastrocnemius, LL proximal weakness assessed by Ilio psoas and quadriceps; UL distal weakness assessed by first dorsal interosseous, abductor pol-
licis brevis, and adductor digiti minimi, UL distal weakness assessed by deltoids, biceps brachii, and triceps. Vibration based on Rydell tuning fork
with “5” on scale of “8” being considered normal and cutaneous based on pinprick sensation: Normal is no decrease compared to the examiner,
Red is reduced, and abs is absent up to level indicated. Both motor and sensory evaluations were based on worst score observed of the two
limbs. CMTNSv2 scores are separable into <10 (mild), 11–20 (moderate), or >20 (severe) impairment.19 CMTPedS scores range from 0 to 44 with
higher numbers suggesting greater disability.20
Table 2. Motor NCVs.
Individual Age Side


































86687-0001 13 L 11.3 7 10 1.4 23.4 9 0.271 – – – NR
86687-0100 9 L 21.6 6 5 0.13 31.6 8 0.280 – – – –
86687-0100 9 R 9.7 8 9 5.3 – – – – – – –
Normal values for each nerve in top row under DML, NCV, and CMAP. DML, distal motor latency; NCV, nerve conduction velocity; NCV1, NCV
between wrist/elbow; NCV2, NCV around elbow; NCV3, NCV between ankle/knee; NCV4, NCV around knee; CMAP, compound muscle action
potential. Bold letters signify abnormal values.
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(MNCV) were severely reduced to between 5 and 10 m/
sec in the upper extremities for both sisters (Table 2).
Sensory nerve conduction velocities were unobtainable
(data not shown).
Genotyping and sequencing mutant PMP22
We extracted RNA from dermal nerve tissue in skin biop-
sies of both the older sister and an unaffected control,
and then amplified the PMP22 transcript by RT-PCR. In
the proband’s lane, we identified two bands: a 552-bp
band that migrated to the size predicted for the normal
PMP22 transcript length, as seen in the positive control
lane, and a 411-bp band that suggests a truncated PMP22
transcript (Fig. 2A). The 141 bp truncation was the pre-
dicted size of PMP22 mRNA for this RT-PCR product for
which exon 4 is deleted (Fig. 2B). We compared tran-
script sequences between the two bands; the sequencing
confirmed an exon 4 in-frame deletion resulted in the
smaller band, with no changes to the sequence at the
PMP22 C-terminus postdeletion (Fig. 2C). Sequencing of
the upper band revealed the full PMP22 coding sequence
from the normal allele including exon 4. The deletion of
exon 4 in the mutant transcript of our proband resulted
in the loss of 47 amino acids (AA#60-106), most of which
comprise the hydrophobic second transmembrane region
of PMP22 protein. Translation of subsequent amino acids
(AA#107-160) was not affected (Figs. 2D and 3).
Figure 2. RT-PCR and sequencing analysis of PMP-22 transcript. RT-PCR products amplified from RNA extracted from the proband and control
skin biopsies and a control sural nerve biopsy. The band of approximately 552 bp corresponds to the normal PMP22 transcript and the smaller
band of approximately 411 bp corresponds to the misspliced PMP22 transcript of the proband. (B) Exon–intron structure of PMP22 shows the
skipping of exon 4 caused by aa417 + 2 T>G. The nucleotide numbers in parenthesis indicate the predicted size of coding sequences for each
transcript; the wild type and the mutant. (C) The PCR products were sequenced. Comparisons between wild-type and mutant transcripts
demonstrate the loss of exon 4.
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PMP22D4 retained in ER in transfection
studies
To determine the consequences of the exon 4 deletion we
performed a series of transient transfection studies. We
introduced the exon 4 deletion PMP22 cDNA into two
separate cultured cell lines: non-neuronal Cos7 cells and
RT4 rat Schwann cells, and investigated their fate in the
transfected cells. The majority of wtPMP22 in transfected
Cos7 localized to the plasma membrane. PMP22D4 pro-
tein frequently formed aggregates intracellularly and failed
to reach the plasma membrane. The aggregates colocal-
ized with calnexin suggesting that they were retained in
the endoplasmic reticulum (ER) (Fig. 4A). We observed a
similar pattern in transfected RT4 Schwann cells under
the same conditions (Fig. 4B).
To further quantify the above changes, we calculated
the percentage of transfected cells demonstrating ER
retention in both PMP22D4 and wild-type transfections.
There was a fivefold higher percentage of Cos7 cells
demonstrating retention of mutant PMP22 than retention
of wtPMP22: 28% to 5.5%, respectively (Fig. 3C). There
was a sixfold higher percentage of RT4 cells that revealed
mutant PMP22 retention in the ER than wtPMP22 reten-
tion: 31.5% to 5%, respectively (Fig. 4C). Because the
transfection efficiency was similar between PMP22D4 and
wild-type studies, because results were similar in two sep-
arate cell types, because aggregates were much less fre-
quent with wild-type experiments, and because studies
were done in triplicate, we believe the results demonstrate
that the PMP22D4 PMP22 mutation resulted in the intra-
cellular aggregation we observed.
We next evaluated how the PMP22D4 mutation
effected trafficking through the Golgi apparatus using the
Golgi antibody marker (giantin). Wild-type PMP22 cDNA
transfected RT4 Schwann cells displayed transport of
wtPMP22 to the plasma membrane as well as some colo-
calization within the Golgi. PMP22D4, as shown above,
did not travel to the plasma membrane. However, its
colocalization within the Golgi did not differ from that of
wild-type PMP22. Specifically, we recorded similar per-
centages of PMP22 colocalization with Golgi between
wtPMP22 (96.2%) and PMP22D4 (98.7%) cDNA trans-
fections (data not shown). Taken together, these results
suggest that PMP22D4 is largely retained in the ER.
Discussion
We have evaluated two sisters with an unusual rearrange-
ment within the PMP22 gene. Although the patient’s
mother is mosaic for this rearrangement, and is thus clin-
ically normal, both daughters had leg weakness beginning
in infancy associated with severely slowed nerve conduc-
tion velocities of <10 m/sec, much slower than that typi-
cal for CMT1A. Consistent with the predicted data from
Zhang and coworkers, based on their observations that
there are exon 4 rearrangements within the PMP22 gene,
our patient is missing all exon 4 sequences within the
mutant PMP22 mRNA, producing a deletion of a portion
of the coding region of this protein. Transfection studies
with a cDNA construct encoding the mutant protein
demonstrate that PMP22D4 is retained within the ER and
is not expressed on the cell surface. Taken together, these
data suggest that PMP22D4 causes CMT1E by a toxic
gain-of-function mechanism.
Three FoSTes/MMBIR events with microhomologies at
breakpoint junctions were previously identified in our
patients by high-density oligonucleotide array comparative
genomic hybridization (aCGH). These events were pre-
dicted to result in at least a partial deletion of exon 4.17
Our RT-PCR, which is based on mRNA expression, con-
firmed this prediction by demonstrating the complete dele-
tion of exon 4 in myelinating Schwann cells in the
proband. Primers used for the RT-PCR spanned the
PMP22 gene from exon 1 to the 30 UTR and were therefore
predicted to detect any splicing abnormalities in the resul-
tant mRNA. Since only the wild-type and exon 4 deleted
bands were observed (Fig. 1), this suggested to us that the
only splicing abnormality that occurred was the deletion of
exon 4. Thus, in the proband, there was no evidence of
variability in spliced products from the exon 4 rearrange-
ment, and we think it unlikely that variability of splicing
caused the transient asymmetry in the younger sister.
We speculated on why there were significant asymme-
tries in the younger sister; in particular, the quadriceps
weakness of the left leg. Because the results from her sis-
ter’s biopsy revealed expression of only wild-type PMP22
and PMP22D4, we considered it unlikely that myelinating
Schwann cells ensheathing the femoral nerve from the
Figure 3. Peripheral myelin protein 22 (PMP22) secondary protein
structure. Amino acids circled in red are encoded by exon 4 which is
deleted in the patients.
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Figure 4. ER retention of PMP22D4. Transient transfection studies were performed in Cos7 (A) and RT4 (B) with WT PMP22 or PMP22D4 DNA
constructs. Arrows point to PMP22D4 (HA) colocalization with the ER (calnexin). Arrowheads demonstrate PMP22 transported to cellular
membrane. In PMP22D4 transfected cells, significantly more cells were retained in the ER compared to wild-type cells (C).
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right leg expressed a different PMP22 mRNA than the left
leg. Furthermore, ultrasound showed no asymmetry of
the femoral nerves. We recognized that HNPP, which is
caused by the deletion of an entire PMP22 allele, is char-
acterized by episodes of asymmetric weakness or sensory
loss, particularly at sites of compression.18 However, there
were no other features that suggested HNPP in either sib-
ling. For example, neither sister had previously noted
transient focal symptoms and their overall presentations
were quite different from those of HNPP. HNPP, a clini-
cal phenotype resulting from PMP22 loss of function, typ-
ically has focal areas of slowing on nerve conduction
studies, but outside of these regions the NCV are often
nearly normal.19 Moreover, outside of the focal episodes,
most patients with HNPP have at least relatively normal
neurological examinations. These two girls were not only
more affected clinically than most patients with HNPP,
but they were also more affected than many patients with
CMT1A which is caused by PMP22 gain of function –
most often resulting from a duplication of PMP22.
Accordingly, we hypothesized that our patients’ pheno-
type is caused by a toxic gain of function caused by the
mutant PMP22 lacking exon 4. Given the recovery of sig-
nificant quadriceps function, this seems to be a superim-
posed problem, perhaps related to an inflammatory
process. However, we were not able to explain the
younger sisters asymmetries based on the specific deletion
of exon 4.
Most PMP22 missense mutations and other mutations
within the PMP22 gene cause neuropathies that are clini-
cally more severe than CMT1A and are therefore also
likely to induce toxic gain of function abnormalities in
myelinating Schwann cells.8 Mutations that cause severe
neuropathies beginning in infancy are said to cause a
Dejerine–Sottas syndrome (DSS) and those that prevent
normal myelination are said to induce congenital
hypomyelination (CHM).8 Met69Lys and Ser72Leu PMP22
have been reported to cause DSS.20 Ser72Leu PMP22 has
also been reported to cause CHO21 as has Cys109Arg
PMP2222 to provide several examples. Alternatively, other
PMP22 mutations have been reported to cause a typical
HNPP phenotype. These include Leu4Ter,9 Leu7 fs,10,11
Gly94 fs,12,23 Tyr97 fs,24 and Thr99 fs25 PMP22. Muta-
tions that cause an HNPP phenotype eliminate the
mutant allele by processes such as nonsense-mediated
decay.11,26 Thus, these are complete loss-of-function alle-
les similar to traditional HNPP in which the PMP22 allele
is deleted.13 How other mutations cause a gain of func-
tion is not known, but clues about mechanisms can be
inferred from studies performed in the naturally occur-
ring Trembler (Tr) and Trembler J (TrJ) mouse models
of CMT1E. Tr and TrJ result from Gly150Asp27 and
Leu16Pro PMP22,28 respectively. Both Tr29 and TrJ30,31
mutations cause DSS in humans, and the mice can be
used to model the human neuropathies. Leu16Pro
PMP22 has been shown to be retained in the ER of Sch-
wann cells in TrJ mice.32 Moreover, the mice have
demonstrated improvement following treatment with cur-
cumin to reduce ER stress.32 Similar results have been
found in two missense mutations in myelin protein zero
(MPZ) that cause CMT1B. The Ser63del and Arg98Cys
MPZ mutations causing CMT1B are retained within the
ER and are thought to cause neuropathy in part by acti-
vating the unfolded protein response (UPR) secondary to
ER stress.33,34 The three arms of the UPR work together
in part to relieve ER stress by reducing the overall transla-
tion of proteins by the cell.35 Therapies directed at reliev-
ing ER stress and attenuating the UPR have improved the
neuropathy of both Ser63del33,36 and Arg98Cys16 mice.
Our data suggest that this process may also occur with
PMP22D4, further expanding the role of ER stress and
UPR activation in the pathogenesis of what are often
more severe forms of CMT1.
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